Altered long noncoding RNAs and survival outcomes in ovarian cancer

Li, Ning; Hu, Yunzhang; Wang, Shu; Lang, Jinghe

doi:10.1097/md.0000000000011481

Cited by 18 publications

(11 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent research has documented the biological role of lncRNAs in OC [7][8][9], and several studies have demonstrated an association between lncRNA expression and patient survival in this cancer [11,12]. There are currently between 32 and 58 lncRNAs that have been reported to have a role in OC pathogenesis [7][8][9].…”

Section: Discussionmentioning

confidence: 99%

The Biological and Clinical Role of the Long Non-Coding RNA LOC642852 in Ovarian Carcinoma

Filippov-Levy

Reich

Davidson

2020

IJMS

View full text Add to dashboard Cite

The objective of the present study was to analyze the biological and clinical role of the long non-coding RNA LOC642852 in ovarian carcinoma (OC). LOC642852 expression was analyzed in seven OC cell lines (OVCAR-3, OVCAR-8, OVCA 433, OVCA 429, OC 238, DOV13, ES-2) and 139 high-grade serous carcinoma (HGSC) specimens (85 effusions, 54 surgical specimens). Following LOC642852 knockout (KO) using the CRISPR/Cas9 system, OVCAR-8 HGSC cells were analyzed for spheroid formation, migration, invasion, proliferation, matrix metalloproteinase (MMP) activity, and expression of cell signaling proteins. OVCAR-8 cells with LOC642852 KO were significantly less motile and less invasive compared to controls, with no differences in spheroid formation, proliferation, or matrix metalloproteinase (MMP) activity. Total Akt and Erk levels were comparable in controls and KO cells, but their phosphorylation was significantly increased in the latter. In clinical specimens, LOC642852 was overexpressed in ovarian tumors and omental/peritoneal metastases compared to effusion specimens (p = 0.013). A non-significant trend for shorter overall (p = 0.109) and progression-free (p = 0.056) survival was observed in patients with HGSC effusions with high LOC642852 levels. Bioinformatics analysis showed potential roles for LOC642852 as part of the TLE3/miR-221-3p ceRNA network and in relation to the FGFR3 protein. In conclusion, LOC642852 inactivation via CRISPR/Cas9 affects cell signaling, motility, and invasion in HGSC cells. LOC642852 is differentially expressed in HGSC cells at different anatomical sites. Its potential role in regulating the TLE3/miR-221-3p ceRNA network and FGFR3 merits further research.

show abstract

Section: Discussionmentioning

confidence: 99%

The Biological and Clinical Role of the Long Non-Coding RNA LOC642852 in Ovarian Carcinoma

Filippov-Levy

Reich

Davidson

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Recently, a meta-analysis has indicated that aberrant expression of lncRNAs is positively correlated with poor survival outcomes in OC. During this study, 11 lncRNAs, including NEAT1, HOTAIR, MALAT1, TC010441, ANRIL, AB073614, CCAT2, ZFAS1, UCA1, SPRY4-IT1, and HOXA11as, were significantly associated with reduced overall survival, progression-free survival, and disease-free survival in OC patients [ 188 ]. Similarly, Luo et al revealed that upregulation of eight lncRNAs; HOTAIR, NEAT1, CCAT2, UCA1, C17orf91, ANRIL, TC0101441, and AB073614 and downregulation of 5 lncRNAs; ASAP1-IT1, AC104699.1.1, LINC00472, FAM215, and RP11-284N8.3.1 were correlated with poor prognosis in OC given a probability for harnessing these lncRNAs as potential prognostic biomarkers for OC [ 189 ].…”

Section: Lncrnas As Diagnostic and Prognostic Biomarkersmentioning

confidence: 99%

Back to the Future: Rethinking the Great Potential of lncRNAS for Optimizing Chemotherapeutic Response in Ovarian Cancer

Elsayed

Amero

Salama

et al. 2020

Cancers

View full text Add to dashboard Cite

Ovarian cancer (OC) is one of the most fatal cancers in women worldwide. Currently, platinum- and taxane-based chemotherapy is the mainstay for the treatment of OC. Yet, the emergence of chemoresistance results in therapeutic failure and significant relapse despite a consistent rate of primary response. Emerging evidence substantiates the potential role of lncRNAs in determining the response to standard chemotherapy in OC. The objective of this narrative review is to provide an integrated, synthesized overview of the current state of knowledge regarding the role of lncRNAs in the emergence of resistance to platinum- and taxane-based chemotherapy in OC. In addition, we sought to develop conceptual frameworks for harnessing the therapeutic potential of lncRNAs in strategies aimed at enhancing the chemotherapy response of OC. Furthermore, we offered significant new perspectives and insights on the interplay between lncRNAs and the molecular circuitries implicated in chemoresistance to determine their impacts on therapeutic response. Although this review summarizes robust data concerning the involvement of lncRNAs in the emergence of acquired resistance to platinum- and taxane-based chemotherapy in OC, effective approaches for translating these lncRNAs into clinical practice warrant further investigation.

show abstract

“…Promisingly, the prognostic value of lncRNAs in ovarian cancer has been documented, which are mostly up-regulated. 16 In the An initial conclusion was comprehended as that LINC00176 was highly expressed in ovarian cancer tissues and cells featured with strengthened cell capabilities of proliferation, migration, invasion and EMT along with weakened apoptotic property. Hitherto, limited studies have enclosed the role of LINC00176 in malignancy.…”

Section: Linc00176 Regulates Cp Expression Via Promotion Of the Intmentioning

confidence: 99%

Knockdown of long non‐coding RNA LINC00176 suppresses ovarian cancer progression by BCL3‐mediated down‐regulation of ceruloplasmin

Dai

Niu

Feng

2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Ovarian cancer is a common malignancy among women with some clinically approved diagnostic coding gene biomarkers. However, long non‐coding RNAs (lncRNAs) have been indicated to play an important role in controlling tumorigenesis of ovarian cancer. Hereby, the aim of the study was to uncover the function of lncRNA LINC00176 in the development and progression of ovarian cancer by regulating ceruloplasmin (CP). Bioinformatics prediction in combination with RT‐qPCR analysis for the expression pattern of LINC00176 revealed that LINC00176 was highly expressed in ovarian cancer tissues as well as in ovarian cancer cell lines, respectively. LINC00176 was predominantly localized in the nucleus. Delivery of si‐LINC00176, oe‐LINC00176, si‐BCL3 and si‐CP plasmids was conducted to explore the effects of LINC00176 on ovarian cancer. Promoted proliferation, migration and invasion along with reduced apoptosis were observed in cells treated with oe‐LINC00176, while si‐BCL3 and si‐CP were able to block the promoting effects. Investigations with regard to the correlation between LINC00176 and promoter region of CP turned out to be positive via B‐cell CLL/lymphoma 3 (BCL3) by means of dual‐luciferase reporter gene assay, ChIP and RIP assays. Furthermore, oncogenic properties of the LINC00176/BCL3/CP axis were also demonstrated by tumour formation in vivo generated upon injecting cells in nude mice. Our results demonstrate that restored LINC00176 initiates tumorigenesis in ovarian cancer by increasing CP expression via recruiting BCL3, the mechanism of which represented a potential and promising therapeutic target for the disease.

show abstract

Altered long noncoding RNAs and survival outcomes in ovarian cancer

Abstract: Supplemental Digital Content is available in the text

Cited by 18 publications

References 51 publications

The Biological and Clinical Role of the Long Non-Coding RNA LOC642852 in Ovarian Carcinoma

The Biological and Clinical Role of the Long Non-Coding RNA LOC642852 in Ovarian Carcinoma

Back to the Future: Rethinking the Great Potential of lncRNAS for Optimizing Chemotherapeutic Response in Ovarian Cancer

Knockdown of long non‐coding RNA LINC00176 suppresses ovarian cancer progression by BCL3‐mediated down‐regulation of ceruloplasmin

Contact Info

Product

Resources

About